Tarsus Pharmaceuticals Partners with John Cena to Drive Demodex Blepharitis Diagnosis Rates

With an estimated 25 million Americans affected by Demodex blepharitis and diagnosis rates remaining low, Tarsus Pharmaceuticals is deploying a celebrity-driven awareness campaign to close the gap between symptom onset and clinical presentation. The Irvine-based company announced on May 14, 2026, that actor and athlete John Cena will front a multi-channel campaign centered on his personal diagnosis and treatment with XDEMVY® (lotilaner ophthalmic solution) 0.25%, the only FDA-approved therapy that directly targets Demodex mite infestation.

For eye care providers and commercial teams, the campaign's clinical hook is specific: collarette presence at the eyelid margin is pathognomonic for Demodex blepharitis, and the condition accounts for over two-thirds of all blepharitis cases. Tarsus is using Cena's account of years of undiagnosed eyelid redness, itching, and crusting to illustrate the diagnostic lag that characterizes this patient population. The campaign will run across media interviews and social content in the coming months.

XDEMVY's clinical profile underpins the commercial rationale. The product was evaluated in two pivotal trials enrolling over 800 patients, with twice-daily dosing over six weeks. Both trials met primary and all secondary endpoints with statistical significance; no serious treatment-related adverse events were reported. The Titan study data, which found collarettes in 58% of patients presenting to U.S. eye care clinics, forms the epidemiological basis for the 25 million prevalence estimate, derived from an annual clinic visit base of at least 45 million.

CEO Bobby Azamian, M.D., Ph.D., framed the initiative around a persistent clinical behavior pattern: patients normalizing ocular irritation rather than seeking evaluation. The campaign's emphasis on routine eye exams as the diagnostic entry point aligns with the straightforward detection method available to providers, a downward gaze examination of the eyelid margin for collarettes, requiring no specialized equipment beyond a standard slit lamp.

Tarsus's ability to convert increased patient awareness into diagnosed and treated cases will depend on whether eye care providers see a corresponding uptick in patients presenting with blepharitis-related complaints following campaign rollout.

Source: Tarsus Pharmaceuticals via GlobeNewswire, May 14, 2026.